harmacare
A Cost-Effectiveness Analysis of Low Risk Deliveries: A Comparison of Midwives, Family Physicians and Obstetricians
Dylan Walters, Archna Gupta, Austin E. Nam, Jennifer Lake, Frank Martino and Peter Coyte
Research Papers
Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
Devidas Menon, Derek Clark and Tania Stafinski
Discussion and Debate
Canada’s New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem
Aidan Hollis and Paul Grootendorst
Research Paper
The Impact of Private Insurance Coverage on Prescription Drug Use in Ontario, Canada
Jillian Kratzer, Lucy Cheng, Sara Allin and Michael R. Law
Research Paper
A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds
Hilary Short, Tania Stafinski and Devidas Menon
Discussion and Debate
Regulating Direct-to-Consumer Drug Information: A Case Study of Eli Lilly’s Canadian 40over40 Erectile Dysfunction Campaign
Jean-Christophe Bélisle Pipon and Bryn Williams-Jones
Data Matters
The Drivers of Overspending on Prescription Drugs in Quebec
Kate Smolina and Steve Morgan
Rapport De Recherche
Trois types de stratégies des fabricants pour la fidélisation aux médicaments de marque
Marie-Claude Prémont and Marc-André Gagnon